Definitive Healthcare Corp.
Close on Oct 19, 2026
- Market cap
- $116.39M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | After market close | $55.20M | $-0.05 | $0.05 |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $55.90M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | After market close | $61.50M | $-0.09 | $0.06 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | $60.00M | $-0.14 | $0.07 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | $60.80M | $-0.07 | $0.07 |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $59.20M | $-0.95 | $0.05 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | After market close | $62.30M | $-0.51 | $0.08 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | $62.70M | $-1.12 | $0.10 |
| Q1 FY2024 Ended Jun 30, 2024 | Aug 5, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 2, 2023 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 10, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | Full Year 2026 | $57.00M to $59.00M | Raised |
| Adjusted EBITDAnon-GAAP | Third Quarter 2026 | $13.50M to $14.50M | New |
| Adjusted Net Income Per Diluted Sharenon-GAAP | Full Year 2026 | $0.18 to $0.20 | Raised |
| Adjusted Net Income Per Diluted Sharenon-GAAP | Third Quarter 2026 | $0.04 to $0.05 | New |
| Adjusted Operating Incomenon-GAAP | Third Quarter 2026 | $10.50M to $11.50M | New |
| Adjusted Operating Incomenon-GAAP | Full Year 2026 | $45.50M to $47.50M | Raised |
| adjusted EBITDA Marginnon-GAAP | Full Year 2026 | 26% to 27% | New |
| adjusted EBITDA Marginnon-GAAP | Third Quarter 2026 | 25% to 27% | New |
| Adjusted Net Incomenon-GAAP | Full Year 2026 | $27.00M to $29.00M | Raised |
| Adjusted Net Incomenon-GAAP | Third Quarter 2026 | $5.50M to $6.50M | New |
| Revenue | Full Year 2026 | $220.00M to $222.00M | Lowered |
| Revenue | Third Quarter 2026 | $54.00M to $55.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Definitive Healthcare filed with the SEC
Special Committee of Definitive Healthcare Board Confirms Receipt of Going-Private Proposal from Advent International
Other events · EX-99.1 to Form 8-K
Definitive Healthcare Reports Financial Results for Second Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Definitive Healthcare Reports Financial Results for First Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2025
Results of operations · EX-99.1 to Form 8-K
Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2025
Results of operations · EX-99.1 to Form 8-K
Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2025
Results of operations · EX-99.1 to Form 8-K
Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025
Results of operations · EX-99.1 to Form 8-K
Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2024
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2024
Results of operations · Executive or director change · Other events · EX-99.1 to Form 8-K
Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2024
Results of operations · EX-99.1 to Form 8-K
Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2024
Results of operations · EX-99.1 to Form 8-K
Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2023
Results of operations · EX-99.1 to Form 8-K
Definitive Healthcare Announces CEO Transition
Results of operations · Executive or director change · EX-99.1 to Form 8-K
As we embark upon this new year, I’m writing to share some critical and difficult changes that we are making to our organization to best position us for the future.
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2023
Results of operations · EX-99.1 to Form 8-K
Definitive Healthcare Names Carrie Lazorchak as Chief Revenue Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Definitive Healthcare Welcomes Scott Stephenson to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Acquisition broadens Definitive Healthcare’s suite of healthcare commercial intelligence solutions with new data, analytics, and visualization tools tailor-built for the provider market
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Definitive Healthcare Reports Preliminary Financial Results for Second Quarter Fiscal
Results of operations · Exit or restructuring costs · Prior financials no longer reliable · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Exit or restructuring costs · Prior financials no longer reliable · Regulation FD disclosure · EX-99.2 to Form 8-K
Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2023
Results of operations · EX-99 to Form 8-K
Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2022
Results of operations · Executive or director change · EX-99 to Form 8-K
Today I’m announcing the most difficult decision that we’ve ever had to make at Definitive Healthcare. We’re reducing the size of our team
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2022
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Definitive Healthcare Names Jon Maack as President Effective November 3, 2022
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Definitive Healthcare Announces Changes to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2022
Results of operations · EX-99.1 to Form 8-K
Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2022
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Definitive Healthcare Names Robert Musslewhite as CEO Effective August 1, 2022
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Definitive Healthcare Reports Financial Results for Fourth Quarter
Results of operations · Other events · EX-99.1 to Form 8-K
Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2021
Results of operations · EX-99.1 to Form 8-K